PCMM
NTLA icon

Private Capital Management (Minnesota)’s Intellia Therapeutics NTLA Stock Holding History

Private Capital Management (Minnesota)’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$87K Sell
3,500
-1,500
-30% -$28.3K 0.1% 159
2017
Q2 		$80K Buy
5,000
+1,000
+25% +$14K 0.09% 166
2017
Q1 		$56K Buy
+4,000
New +$53.7K 0.06% 179

Other funds holding NTLA

AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
GTP
Global Thematic Partners New York $120M AUM 25.18% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $1.92B AUM 70.51% 1-Year Est. Return

Private Capital Management (Minnesota)'s NTLA Position: Q3 2017 in Review

Private Capital Management (Minnesota) reduced its Intellia Therapeutics (NTLA) stake by 30% in Q3 2017, selling an estimated $28.3K and leaving 3,500 shares worth $87K. The position accounts for 0.1% of the portfolio, ranked #159.

Private Capital Management (Minnesota) first reported a position in NTLA in Q1 2017 and has held it in 3 quarters since. 85 funds tracked by Wall St. Rank hold NTLA as of Q3 2017.

  • Private Capital Management (Minnesota) held 3,500 shares of Intellia Therapeutics worth $87K as of Q3 2017.
  • Private Capital Management (Minnesota) sold 1,500 Intellia Therapeutics shares in Q3 2017, an estimated $28.3K.
  • Intellia Therapeutics made up 0.1% of Private Capital Management (Minnesota)'s portfolio in Q3 2017, its #159 holding.
  • Private Capital Management (Minnesota) first reported a position in Intellia Therapeutics in Q1 2017 and has held it in 3 quarters since.
  • 85 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2017.

Based on Private Capital Management (Minnesota)'s 13F filing for Q3 2017, filed 26 Oct 2017.